Symbiox Investment & Trading Q1 Results: Net profit rises 15.5% YoY

2 min read     Updated on 12 Aug 2026, 06:15 PM
scanx
Reviewed by
Jubin VScanX News Team
AI Summary

Symbiox Investment & Trading Co Ltd posted a net profit of ₹7.73 lakh in Q1FY27, up 15.5% YoY, despite revenue falling 44.3% to ₹25.53 lakh. The profit growth was driven by a 59.2% drop in total expenses, including zero purchases of stock-in-trade. EPS rose to ₹0.025 from ₹0.021.

powered bylight_fuzz_icon
48084302

*this image is generated using AI for illustrative purposes only.

Symbiox Investment & Trading Co Ltd reported a net profit of ₹7.73 lakh for the quarter ended June 30, 2026, marking a 15.5% year-on-year increase from ₹6.69 lakh in Q1FY26. This profit growth occurred despite a significant 44.3% decline in revenue from operations, which dropped to ₹25.53 lakh from ₹45.81 lakh in the prior year period. The divergence between falling revenue and rising profitability highlights a shift in the company's cost structure and operational efficiency during the quarter.

The Board of Directors approved the unaudited financial results on August 12, 2026, at its second meeting for the fiscal year 2026-27. The meeting, held at the company’s registered office in Kolkata, also adopted the limited review report issued by the statutory auditor, SSRV & Associates. The results were prepared in accordance with Indian Accounting Standard 34 (Ind AS 34) and Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Financial Performance Overview

Revenue from operations declined sharply to ₹25.53 lakh in Q1FY27, compared to ₹45.81 lakh in Q1FY26. This drop was primarily attributed to a reduction in purchases of stock-in-trade, which fell to zero from ₹9.48 lakh in the previous year, and lower changes in inventories, which decreased to nil from ₹13.80 lakh. Total income followed a similar trajectory, standing at ₹25.53 lakh against ₹46.00 lakh in the corresponding quarter of FY26.

Particulars Q1FY27 (₹ Lakh) Q1FY26 (₹ Lakh) Change (%)
Revenue From Operations 25.53 45.81 -44.3
Other Income 0.00 0.19 -100.0
Total Expenses 15.08 36.96 -59.2
Profit Before Tax 10.45 9.04 15.6
Net Profit After Tax 7.73 6.69 15.5

Total expenses contracted significantly by 59.2% to ₹15.08 lakh, down from ₹36.96 lakh in Q1FY26. Employee benefits expense rose slightly to ₹6.04 lakh from ₹4.07 lakh, while other expenses decreased marginally to ₹8.97 lakh from ₹9.54 lakh. Depreciation remained stable at ₹0.07 lakh. The substantial reduction in total costs outpaced the decline in revenue, contributing to the improved bottom line.

What the Numbers Show

The key analytical observation is the decoupling of revenue and profit trends. While top-line revenue nearly halved due to lower trading activity (evidenced by zero purchases of stock-in-trade), the company managed to increase its net profit. This suggests that the company’s fixed cost base is low relative to its variable costs, or that the mix of remaining revenue was more profitable. The absence of finance costs and minimal depreciation further supports a lean operational model. However, the reliance on inventory changes for revenue recognition in previous periods versus none in the current quarter indicates volatility in trading volumes.

Earnings per share (basic) rose to ₹0.025 from ₹0.021 in the previous year’s first quarter. The paid-up equity share capital remained unchanged at 31,287,330 shares with a face value of ₹10.00 each. The statutory auditor, SSRV & Associates, issued an unqualified review report, confirming that the financial statements present a true and fair view in accordance with applicable accounting standards.

Historical Stock Returns for Symbiox Investment & Trading

1 Day5 Days1 Month6 Months1 Year5 Years
0.0%+2.34%+8.70%-12.06%-30.28%+27.74%

Will the company's strategy of minimizing trading volume to preserve margins be sustainable in Q2FY27, or is a return to higher revenue growth expected?

How does the complete cessation of stock-in-trade purchases impact Symbiox's long-term competitive positioning and client relationships in the investment sector?

What specific operational efficiencies drove the 59.2% reduction in total expenses, and can these cost-saving measures be maintained as business activity potentially normalizes?

Symbiox Investment & Trading
View Company Insights
View All News
like20
dislike

Symbiox FY26 net profit at ₹15.23 lakh, revenue declines

1 min read     Updated on 29 May 2026, 12:19 PM
scanx
Reviewed by
Suketu GScanX News Team
AI Summary

Symbiox Investment & Trading Co. Ltd. released its audited financial results for the year ended March 31, 2026, reporting a decline in net profit to ₹15.23 lakh and revenue to ₹160.29 lakh. The board approved the re-appointment of the Secretarial Auditor and Internal Auditor for FY 2026-27, and the statutory auditors issued an unmodified opinion.

powered bylight_fuzz_icon
41075957

*this image is generated using AI for illustrative purposes only.

Symbiox Investment & Trading Co. Ltd. reported a net profit of ₹15.23 lakh for the year ended March 31, 2026, a decline from ₹19.19 lakh in the previous year. Revenue from operations fell to ₹160.29 lakh from ₹276.36 lakh in FY25. The board of directors approved the audited financial results during a meeting held on May 23, 2026.

Financial Performance

For the year ended March 31, 2026, total income stood at ₹160.52 lakh. Total expenses decreased to ₹139.94 lakh from ₹250.86 lakh in the prior year. Profit before tax for FY26 was ₹20.58 lakh, compared to ₹25.93 lakh in FY25. The basic earnings per share (EPS) for the year were ₹0.049, down from ₹0.061 in the previous year.

The financial performance for the quarter ended March 31, 2026, showed a net profit of ₹1.22 lakh on a revenue of ₹82.73 lakh. In comparison, the quarter ended March 31, 2025, had reported a net loss of ₹29.94 lakh.

Particulars Year Ended 31-03-2026 (₹ in Lakh) Year Ended 31-03-2025 (₹ in Lakh)
Revenue From Operations 160.29 276.36
Total Income 160.52 276.79
Total Expenses 139.94 250.86
Profit Before Tax 20.58 25.93
Net Profit 15.23 19.19
Basic EPS 0.049 0.061

Balance Sheet and Cash Flow

As of March 31, 2026, the company's total assets were valued at ₹3,197.60 lakh, slightly higher than ₹3,196.59 lakh in the previous year. Total equity stood at ₹3,187.63 lakh, while total liabilities were reported at ₹9.97 lakh.

The cash flow statement for the year ended March 31, 2026, showed a net cash flow from operating activities of ₹272.59 lakh. Net cash used in investing activities was ₹261.29 lakh. Consequently, the net cash flow during the year was ₹11.30 lakh, bringing the closing cash and cash equivalents to ₹117.18 lakh.

Board Appointments

The board approved the re-appointment of Mr. Akhil Agarwal, Practising Company Secretary, as the Secretarial Auditor for FY 2026-27. The board also re-appointed Mrs. Shikha Singhal Chartered Accountants as the Internal Auditor for the same financial year. The statutory auditors issued an unmodified opinion on the audited financial results.

Historical Stock Returns for Symbiox Investment & Trading

1 Day5 Days1 Month6 Months1 Year5 Years
0.0%+2.34%+8.70%-12.06%-30.28%+27.74%

What strategic initiatives will Symbiox implement to reverse the decline in revenue from operations?

How does the company plan to utilize the net cash flow generated from operating activities to drive future growth?

Will the significant reduction in total expenses impact the company's long-term operational capabilities?

Symbiox Investment & Trading
View Company Insights
View All News
like17
dislike

More News on Symbiox Investment & Trading

1 Year Returns:-30.28%